Novel Pharmacological Approaches for Multidrug‐Resistant Tuberculosis: Review

Abstract

Background: Due to its resistance to common anti-TB drugs, multidrug-resistant tuberculosis (MDR-TB) presents substantial treatment problems. Optimizing therapeutic outcomes requires individualized treatment plans that take into account patient comorbidities, medication susceptibility profiles, and past treatment history. The significance of individualized medication in the treatment of MDR-TB is emphasized in this study. Methods of Review: Current research on tailored treatment plans for MDR-TB is summarized in this review. It highlights how pharmacogenomics, medication sensitivity testing, and patient-centered care can be used to customize treatment plans. The utilization of combination therapies, monitoring and adaptation techniques, and novel treatment options-such as adjuvant therapy and newer agents-are also covered in the review. Findings: Important findings show that thorough medication susceptibility testing is essential for directing wise treatment decisions. Dosage modifications based on individual metabolic responses can be informed by pharmacogenomic data. Treatment regimen adherence is improved when patients participate in decision-making. Combination therapy involving new drugs has demonstrated potential for increasing therapeutic effectiveness while reducing the emergence of resistance. Frequent monitoring makes it possible to promptly modify therapy in response to the patient response. Conclusions: Treatment for MDR-TB must be individualized and comprehensive due to its complexity. For individuals with MDR-TB, therapy outcomes can be greatly enhanced while lowering the risk of further resistance by combining host-directed therapies, pharmacological breakthroughs, and continuous patient monitoring. Enhancing customized care solutions in this difficult field of infectious illness management requires ongoing research and innovation.